Malignant Reproductive System Neoplasm

TMPRSS2-ETV1 fusions are recurrent in prostate cancers.

PMID 16254181 · Tomlins et al., 2005 · Open in CIViC

Non-invasive detection of multiple TMPRSS2:ERG fusion mutations in urine samples of patients with prostate cancer. Rapid 60 minute screening using DNA ligase and isothermal amplification to detect m… (full text at CIViC)

PMID 27865106 · Koo et al., 2017 · Open in CIViC

Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with … (full text at CIViC)

PMID 19648970 · Litzow et al., 2010 · Open in CIViC

In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for p53 alteration (p53 mutation or p5… (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had u… (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

This study examined the combined effects of APR-246 and doxorubicin in doxorubicin-resistant ovarian cancer cell lines. It revealed a decrease in IC50 value for doxorubicin from 0.95±0.11 μM to 0.12±0… (full text at CIViC)

PMID 26086967 · Mohell et al., 2015 · Open in CIViC

The combination effect of APR-246 and cisplatin was studied in cisplatin-resistant ovarian cancer cell lines. A decrease in IC50 value from 52±11 to 3.2±0.8 μM (p <0.05) for cisplatin was recorded in… (full text at CIViC)

PMID 26086967 · Mohell et al., 2015 · Open in CIViC

p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/r… (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds rat… (full text at CIViC)

PMID 11535556 · Klug et al., 2001 · Open in CIViC

A preclinical study was testing the neomorphic effects of TP53-R175H mutation. Multiple human endometrial cancer KLE cell lines were categorized into different groups: Untransfected cells, Vector (ve… (full text at CIViC)

PMID 19917135 · Dong et al., 2009 · Open in CIViC

As seen in Figure 1, the R213* mutation is predominantly found in colorectal and breast cancers. The variant was described as being a frequent p53 nonsense mutation in melanoma, kidney chromophobe, es… (full text at CIViC)

PMID 28249646 · Panaccione et al., 2017 · Open in CIViC

Most common oncomorphic TP53 mutations are at positions R273, R248, R175, and Y220. Mutant R248Q confers chemoresistance to doxorubicin and paclitaxel. In vitro studies, cells with oncomorphic p53 de… (full text at CIViC)

PMID 24065105 · Brachova et al., 2013 · Open in CIViC

Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

56-year-old women was diagnosed with a stage IV ovarian cancer. Debulking surgery, and chemotherapy was given for 10 months. However, disease recurred and at this time NGS was performed which detected… (full text at CIViC)

PMID 35251641 · Endo et al., 2022 · Open in CIViC

Prostate cancer cell lines over-expressing TSPYL1 P62S had similar levels of cell proliferation as control cells normally expressing TSPYL1 wildtype when treated with abiraterone. Authors note that TS… (full text at CIViC)

PMID 29027195 · Qin et al., 2018 · Open in CIViC

In a prospective clinical trial, 87 metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone acetate/prednisone (AA/P) showed that TSPYL1 R62S (NC_000006.11:g.11660081… (full text at CIViC)

PMID 29027195 · Qin et al., 2018 · Open in CIViC

Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.

PMID 24782778 · Russell et al., 2014 · Open in CIViC

Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed anaplastic lymphoma kinase gene … (full text at CIViC)

PMID 26942346 · Forde et al., 2016 · Open in CIViC

This phase II trial evaluated the efficacy of bevacizumab+erlotinib in 40 platinum-resistant ovarian cancer patients. No evidence was found associating VEGFR-1 expression and any clinical parameters.… (full text at CIViC)

PMID 21041183 · Chambers et al., 2010 · Open in CIViC

Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro.

PMID 22016507 · Wittinger et al., 2011 · Open in CIViC

The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (g… (full text at CIViC)

PMID 16875718 · Chung et al., 2006 · Open in CIViC

ZNF217 was overexpressed in 60% of ovarian tumour samples (26/44) as demonstrated by immunohistochemistry (IHC). Patients with ZNF217 expression had significantly shorter disease-free survival compare… (full text at CIViC)

PMID 25031722 · Li et al., 2014 · Open in CIViC